

## **ESC Declaration of Interests Report**

### **2025 ESC Clinical Consensus Statement on mental health and cardiovascular disease**

All experts contributing to the development of ESC Guidelines/Clinical Consensus Statements developed under the auspices of the Clinical Practice Guidelines Committee must adhere to the *ESC Declaration and Management of Conflicts of Interest Policy*, ensuring transparency and ethical integrity throughout the document development process.

In accordance with this policy, they are required to submit a yearly Declaration of Interests (DOI). Each DOI undergoes a review based on established policy criteria, as defined in the policy's annex 3, enabling continuous assessment and management of potential conflicts of interest.

For this Clinical Consensus Statement, the DOI assessment process began in 2023, evaluating declarations from 2022, and continued in 2024 and 2025—each year including an assessment of interests declared in the preceding calendar year.

Accordingly, for Task Force members, this report includes information declared for years 2022 through 2024. For reviewers, this report includes information declared for years 2023 and 2024.

Experts developing this Clinical Consensus Statement have committed to upholding compliance with the policy criteria through 2025, including adherence to a 10,000 EUR threshold for personal payments.

The latest version of the policy and its annexes can be accessed on the ESC website at [www.escardio.org/DOI](http://www.escardio.org/DOI).

## 2025 Clinical Consensus Statement on mental health and CVD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert               | Type of Relationship with Industry  |
|----------------------|---|
| Braunschweig Frieder | <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b><br/>           Biotronik : Device Therapy, Chronic Heart Failure<br/>           Medtronic Foundation : Device Therapy, Chronic Heart Failure</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b><br/>           Astra Zeneca : Arrhythmias, General<br/>           Pfizer : Arrhythmias, General, Chronic Heart Failure<br/>           Biosense Webster : Atrial Fibrillation (AF)<br/>           Boehringer-Ingelheim : Chronic Heart Failure<br/>           Orion : Device Therapy, Chronic Heart Failure<br/>           Novartis : History of Cardiology</p> |

## 2025 Clinical Consensus Statement on mental health and CVD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert               | Type of Relationship with Industry   |
|----------------------|--|
| Braunschweig Frieder | <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b></p> <p>Folksam Foundation</p> <p>Stockholm County Council</p> <p>Swedish Heart and Lung Foundation</p> <p>Swedish Innovation Agency (Vinnova)</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b></p> <p>Biotronik : Device Therapy, Chronic Heart Failure</p> <p>Medtronic Foundation : Device Therapy, Chronic Heart Failure</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b></p> <p>Astra Zeneca : Arrhythmias, General</p> <p>Pfizer : Arrhythmias, General, Chronic Heart Failure</p> <p>Biosense Webster : Atrial Fibrillation (AF)</p> <p>Boehringer-Ingelheim : Chronic Heart Failure</p> <p>Orion : Device Therapy, Chronic Heart Failure</p> <p>Novartis : History of Cardiology</p> |

## 2025 Clinical Consensus Statement on mental health and CVD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert               | Type of Relationship with Industry  |
|----------------------|---|
| Braunschweig Frieder | <p><b>2024</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> Folksam Foundation<br/> Stockholm County Council<br/> Swedish Heart and Lung Foundation<br/> Swedish Innovation Agency (Vinnova)</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Biotronik : Device Therapy, Chronic Heart Failure<br/> Medtronic Foundation : Device Therapy, Chronic Heart Failure</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Astra Zeneca : Arrhythmias, General<br/> Pfizer : Arrhythmias, General, Chronic Heart Failure<br/> Biosense Webster : Atrial Fibrillation (AF)<br/> Boehringer-Ingelheim : Chronic Heart Failure<br/> Orion : Device Therapy, Chronic Heart Failure<br/> Novartis : History of Cardiology</p> |
| Buccheri Sergio      | <p><b>2022</b> Nothing to be declared</p> <p><b>2023</b> Nothing to be declared</p> <p><b>2024</b> <b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br/> Abbott : Valvular Heart Disease</p>   |

## 2025 Clinical Consensus Statement on mental health and CVD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert       | Type of Relationship with Industry   |
|--------------|--|
| Bueno Hector | <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b><br/> Organon : Cardiovascular Disease in Special Populations<br/> Astra Zeneca : Chronic Heart Failure<br/> Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)<br/> Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b><br/> Boehringer-Ingelheim : EMPACT-MI (EMPAGliflozin vs placebo in patients with AMI), PI<br/> Janssen-Cilag : PACIFIC-MI (Phase 2 RCT milvexian vs placebo following an AMI), PI<br/> Novartis : PARADISE-MI (RCT Sacubitril-valsartan vs ramipril post-AMI), Principal investigator<br/> Astrazeneca : The Clinical Outcomes, HEalthcare REsource Utilization, and relaTed costs (COHERENT) – Heart Failure and COPD Project, Lead investigator, COHERENT</p>  |
|              | <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> Instituto de Salud Carlos III (ISCIII)<br/> Sociedad Española de Cardiología</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Organon : Cardiovascular Disease in Special Populations<br/> Astra Zeneca : Chronic Heart Failure<br/> Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)<br/> Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/> Boehringer-Ingelheim : EMPACT-MI (EMPAGliflozin vs placebo in patients with AMI), PI<br/> Janssen-Cilag : PACIFIC-MI (Phase 2 RCT milvexian vs placebo following an AMI) and Librexia ACS Phase 3 RCT, PI &amp; Nat. coordinator Librexia<br/> Astrazeneca : The Clinical Outcomes, HEalthcare REsource Utilization, and relaTed costs (COHERENT) – Heart Failure and COPD Project, Lead investigator, COHERENT</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert         | Type of Relationship with Industry   |
|----------------|--|
| Bueno Hector   | <p><b>2024</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> European Union<br/> Instituto de Salud Carlos III (ISCIII)<br/> Sociedad Española de Cardiología</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Organon : Cardiovascular Disease in Special Populations<br/> Astra Zeneca : Chronic Heart Failure<br/> Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/> Boehringer-Ingelheim : EMPACT-MI (EMPAgliflozin vs placebo in patients with AMI), PI<br/> Janssen-Cilag : PACIFIC-MI (Phase 2 RCT milvexian vs placebo following an AMI) and Librexia ACS Phase 3 RCT, PI &amp; Nat. coordinator<br/> Librexia<br/> Astrazeneca : The Clinical Outcomes, HEalthcare REsource Utilization, and relaTted costs (COHERENT) – Heart Failure and COPD Project, Lead investigator, COHERENT</p> |
| Deaton Christi | <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b><br/> Astra Zeneca : Chronic Heart Failure</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br/> British Heart Foundation, British Society for Heart Failure, British Cardiovascular Society, American Heart Association</p> <hr/> <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> Evelyn Trust Charity<br/> National Institutes of Health Research</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br/> British Heart Foundation, British Society for Heart Failure, British Cardiovascular Society, American Heart Association</p>   |

## 2025 Clinical Consensus Statement on mental health and CVD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                | Type of Relationship with Industry  |
|-----------------------|---|
| Deaton Christi        | <p><b>2024</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> Evelyn Trust Charity<br/> National Institutes of Health Research</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br/> British Heart Foundation, British Society for Heart Failure, British Cardiovascular Society, American Heart Association, American College of Cardiology</p>  |
| Dragan Simona Ruxanda | <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b><br/> Astra Zeneca : Chronic Heart Failure<br/> Boehringer-Ingelheim : Chronic Heart Failure<br/> Viatris : Hypertension<br/> Berlin Chemie AG : Pharmacology and Pharmacotherapy</p> <p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Astra Zeneca : Chronic Heart Failure<br/> Boehringer-Ingelheim : Chronic Heart Failure<br/> Viatris : Hypertension<br/> Berlin Chemie AG : Pharmacology and Pharmacotherapy</p> <p><b>2024</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Astra Zeneca : Chronic Heart Failure<br/> Boehringer-Ingelheim : Chronic Heart Failure<br/> Merck Sharp &amp; Dohme : Hypertension<br/> Viatris : Hypertension<br/> Hemex : Other</p> |

## 2025 Clinical Consensus Statement on mental health and CVD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert               | Type of Relationship with Industry  |
|----------------------|---|
| Farrero Torres Marta | <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b><br/> Astra Zeneca : Chronic Heart Failure<br/> Boehringer-Ingelheim : Chronic Heart Failure<br/> Novartis : Chronic Heart Failure<br/> Novo-Nordisk : Chronic Heart Failure</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b><br/> Astra Zeneca : Chronic Heart Failure<br/> Novartis : Chronic Heart Failure</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b><br/> Abbott : Device Therapy</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br/> Advocacy committee for the International Society for Heart and Lung Transplantation</p> |
|                      | <p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Astra Zeneca : Chronic Heart Failure<br/> Boehringer-Ingelheim : Chronic Heart Failure<br/> Novartis : Chronic Heart Failure<br/> Novo-Nordisk : Chronic Heart Failure</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Astra Zeneca : Chronic Heart Failure<br/> Novartis : Chronic Heart Failure</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br/> Abbott : Device Therapy</p>   |

## 2025 Clinical Consensus Statement on mental health and CVD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert               | Type of Relationship with Industry |  |
|----------------------|------------------------------------|--|
| Farrero Torres Marta | <b>2024</b>                        | <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Astra Zeneca : Chronic Heart Failure<br/> Boehringer-Ingelheim : Chronic Heart Failure<br/> Novartis : Chronic Heart Failure<br/> Novo-Nordisk : Chronic Heart Failure</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Astra Zeneca : Chronic Heart Failure<br/> Novartis : Chronic Heart Failure</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br/> Abbott : Device Therapy</p> |
|                      |                                    |  |
| Forsyth Faye         | <b>2022</b>                        | Nothing to be declared   |
|                      | <b>2023</b>                        | <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> Evelyn Trust</p>   |
|                      | <b>2024</b>                        | <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> Evelyn Trust</p>  |
| Gevaert Sofie        | <b>2022</b>                        | Nothing to be declared   |
|                      | <b>2023</b>                        | Nothing to be declared   |
|                      | <b>2024</b>                        | <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Boehringer-Ingelheim : Acute Heart Failure</p>  |

## 2025 Clinical Consensus Statement on mental health and CVD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert     | Type of Relationship with Industry  |
|------------|---|
| Held Claes | <b>2022</b><br><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b><br>Coala Life : Arrhythmias, General<br>Boehringer-Ingelheim : Chronic Heart Failure<br>Pharmacosmos : Chronic Heart Failure<br>Amarin : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)<br><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b><br>Bayer AG : Arrhythmias, General, Chronic Heart Failure, Acute Coronary Syndromes, Valvular Heart Disease  |
|            | <b>2023</b><br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Coala Life : Arrhythmias, General<br>Boehringer-Ingelheim : Chronic Heart Failure<br>Pharmacosmos : Chronic Heart Failure<br>Astrazeneca : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)<br>Novo Nordisk : Risk Factors and Prevention<br><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Bayer AG : Arrhythmias, General, Chronic Heart Failure, Acute Coronary Syndromes, Valvular Heart Disease<br><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br>Editor in chief for the official journal of Swedish Society of Cardiology (Svensk Kardiologi). No financial interest. |
|            | <b>2024</b><br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Boehringer-Ingelheim : Chronic Heart Failure<br>Amarin : Risk Factors and Prevention<br>Novo Nordisk : Risk Factors and Prevention  |

## 2025 Clinical Consensus Statement on mental health and CVD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert            | Type of Relationship with Industry  |
|-------------------|---|
| Held Claes        | <b>2024</b> <b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br>Editor in chief for the official journal of Swedish Society of Cardiology (Svensk Kardiologi). No financial interest.  |
| Kurpas Donata     | <b>2022</b> Nothing to be declared  |
|                   | <b>2023</b> Nothing to be declared  |
|                   | <b>2024</b> Nothing to be declared  |
| Ladwig Karl-Heinz | <b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b><br>Amgen Inc : Risk Factors and Prevention, Cardiovascular Disease in Special Populations  |
|                   | <b>2023</b> <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Idorsia : Risk Factors and Prevention, Cardiovascular Disease in Special Populations   |
|                   | <b>2024</b> Nothing to be declared  |
| Lionis Christos   | <b>2022</b> <b>Receipt of royalties for intellectual property.</b><br>Olvos Science : Other<br><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b><br>PFIZER INC. Independent Medical Education Grant : Enhancing skills for addressing vaccine hesitancy among medically undeserved and economically deprived people on the island of Crete throughout the management of the Specific Accou, Scientific Responsible<br>GILEAD SCIENCES INC : Research grant to the Clinic of Social and Family Medicine entitled "DEVELOPING, IMPLEMENTING AND EVALUATING A CLINICAL CARE PATHWAY FOR NASH/NAFLS PRIMARY CARE PATIENTS: A MULTI-C, Scientific Responsible   |
|                   | <b>2023</b> <b>Receipt of royalties for intellectual property.</b><br>Olvos Science : Other<br><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br>PFIZER INC. Independent Medical Education Grant : Enhancing skills for addressing vaccine hesitancy among medically undeserved and economically deprived people on the island of Crete throughout the management of the Specific Accou, Scientific Responsible<br>GILEAD SCIENCES INC : Research grant to the Clinic of Social and Family Medicine entitled "DEVELOPING, IMPLEMENTING AND EVALUATING A CLINICAL CARE PATHWAY FOR NASH/NAFLS PRIMARY CARE PATIENTS: A MULTI-C, Scientific Responsible |

## 2025 Clinical Consensus Statement on mental health and CVD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert             | Type of Relationship with Industry |  |
|--------------------|------------------------------------|--|
| Lionis Christos    | <b>2024</b>                        | <p><b>Receipt of royalties for intellectual property.</b><br/>Olvos Science : Other</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/>GILEAD SCIENCES INC Independent education and research grant : DEVELOPING, IMPLEMENTING AND EVALUATING A CLINICAL CARE PATHWAY FOR NASH/NAFLD TO SERVE PRIMARY CARE PATIENTS IN THREE EUROPEAN SETTINGS, Scientific Coordinator</p> <p>PFIZER INC. Independent Medical Education Grant : Enhancing skills of frontline workforce for addressing vaccine hesitancy among medically undeserved and economically deprived people on the island of Crete , Coordinator</p> |
| Maas Angela        | <b>2022</b>                        | <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b><br/>Organon : Cardiovascular Disease in Special Populations</p>  |
|                    | <b>2023</b>                        | <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Organon : Cardiovascular Disease in Special Populations</p>   |
|                    | <b>2024</b>                        | Nothing to be declared   |
| Mersa Caius Ovidiu | <b>2022</b>                        | <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br/>Romanian Heart Foundation</p>  |
|                    | <b>2023</b>                        | Nothing to be declared   |
|                    | <b>2024</b>                        | Nothing to be declared   |
| Mindham Richard    | <b>2022</b>                        | <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b><br/>PASSpaces. <a href="http://passpaces.co.uk/">http://passpaces.co.uk/</a>. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b><br/>European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p>   |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert          | Type of Relationship with Industry   |
|-----------------|--|
| Mindham Richard | <p><b>2022</b></p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br/>I support the British charity CardiomyopathyUK, <a href="https://www.cardiomyopathy.org.uk/">https://www.cardiomyopathy.org.uk/</a>. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, <a href="https://pumpingmarvellous.org/">https://pumpingmarvellous.org/</a>. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, <a href="https://bureaucracyincts.eu/">https://bureaucracyincts.eu/</a>. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b><br/>I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not not control the purchase &amp; sale of shares and I do not know whether any shares are in medical companies.</p>   |
|                 | <p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>NiCE (National Institute for Health &amp; Care Excellence) - UK Government body. Guideline development.. Commences January 2024. : Chronic Heart Failure</p> <p>PASSpaces. <a href="http://passpaces.co.uk/">http://passpaces.co.uk/</a>. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br/>European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br/>I support the British charity CardiomyopathyUK, <a href="https://www.cardiomyopathy.org.uk/">https://www.cardiomyopathy.org.uk/</a>. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, <a href="https://pumpingmarvellous.org/">https://pumpingmarvellous.org/</a>. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, <a href="https://bureaucracyincts.eu/">https://bureaucracyincts.eu/</a>. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/>I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not not control the purchase &amp; sale of shares and I do not know whether any shares are in medical companies.</p> |

## 2025 Clinical Consensus Statement on mental health and CVD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                   | Type of Relationship with Industry |  |
|--------------------------|------------------------------------|--|
| Mindham Richard          | <b>2024</b>                        | <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> National Institute for Health and Clinical Excellence : Chronic Heart Failure<br/> National Institute for Prevention and Cardiovascular Health (NIPC), Ireland : Rehabilitation and Sports Cardiology, Training and Education<br/> PASSpaces : Training and Education</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br/> Cardiomyopathy UK, a British charity, registered with the government. I support the charity with donations. Heart Failure Warriors, a British charity, registered with the government. I have transferred all of the fees from NIPC (please see 2A) to HF Warriors.</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/> Patient member of advisory board to two Horizon-funded programmes: RAPHAEL (investigating HF palliation) and More-EUROPA (investigating Real World Data in healthcare). I receive no payments from these programmes. Patient member of UK Digital, a UK study researching patients' expectations from digital technology. I receive no payment from UK Digital. I attended the kick-off event where my train fare, hotel bill and dinner were paid for by the study.</p> |
| Rojnic Kuzman Martina    | <b>2022</b>                        | <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b><br/> Janssen-Cilag : Other</p>   |
|                          | <b>2023</b>                        | <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> Zagreb School of Medicine</p>  |
|                          | <b>2024</b>                        | Nothing to be declared   |
| Schmidt Pedersen Susanne | <b>2022</b>                        | Nothing to be declared   |
|                          | <b>2023</b>                        | Nothing to be declared   |

## 2025 Clinical Consensus Statement on mental health and CVD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                   | Type of Relationship with Industry  |
|--------------------------|---|
| Schmidt Pedersen Susanne | <p><b>2024</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Biotronik : e-Cardiology/Digital Health</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br/>Biotronik : e-Cardiology/Digital Health<br/>Biotronik : e-Cardiology/Digital Health</p>  |
| Szmit Sebastian          | <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b><br/>Amgen : Cardiovascular Disease in Special Populations<br/>Bayer : Cardiovascular Disease in Special Populations<br/>Pfizer : Cardiovascular Disease in Special Populations<br/>Bristol Myers Squibb : Cardiovascular Disease in Special Populations</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b><br/>Pfizer : Cardiovascular Disease in Special Populations</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b><br/>Investigator of the API-CAT study.</p> <p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Bayer : Cardiovascular Disease in Special Populations<br/>Janssen-Cilag : Cardiovascular Disease in Special Populations<br/>Pfizer : Cardiovascular Disease in Special Populations<br/>Bristol Myers Squibb : Cardiovascular Disease in Special Populations<br/>Astellas : Cardiovascular Disease in Special Populations<br/>Recordati International : Cardiovascular Disease in Special Populations</p> |

## 2025 Clinical Consensus Statement on mental health and CVD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert               | Type of Relationship with Industry |   |
|----------------------|------------------------------------|---|
| Szmit Sebastian      | <b>2023</b>                        | <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/>           Section Editor of Cardio-Oncology (the official journal of the International Cardio-Oncology Society) International Advisor of JACC: CardioOncology (journal of the American College of Cardiology) Chair of Supportive Care, Polish Society of Clinical Oncology Chair of Education Committee, International Cardio-Oncology Society</p>   |
|                      | <b>2024</b>                        | <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>           Amgen : Cardiovascular Disease in Special Populations<br/>           Astra Zeneca : Cardiovascular Disease in Special Populations<br/>           Pfizer : Cardiovascular Disease in Special Populations<br/>           Bristol Myers Squibb : Cardiovascular Disease in Special Populations<br/>           AbbiVie : Cardiovascular Disease in Special Populations</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/>           Section Editor of Cardio-Oncology (the official journal of the International Cardio-Oncology Society) International Advisor of JACC: CardioOncology (journal of the American College of Cardiology) Associate Editor of Cardiology Journal Editorial Board of Journal of Thrombosis and Thrombolysis Chair of Supportive Care Section, Polish Society of Clinical Oncology Chair of Education Committee, International Cardio-Oncology Society</p> |
| Taylor Rod S         | <b>2022</b>                        | Nothing to be declared  |
|                      | <b>2023</b>                        | <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br/>           BACPR</p>  |
|                      | <b>2024</b>                        | <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br/>           BACPR</p>   |
| Uchmanowicz Izabella | <b>2022</b>                        | Nothing to be declared  |
|                      | <b>2023</b>                        | Nothing to be declared  |
|                      | <b>2024</b>                        | Nothing to be declared  |
| Vilchinsky Noa       | <b>2022</b>                        | <p><b>Receipt of royalties for intellectual property.</b><br/>           Wiley Blackwell : Other</p>  |

## 2025 Clinical Consensus Statement on mental health and CVD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert         | Type of Relationship with Industry |   |
|----------------|------------------------------------|---|
| Vilchinsky Noa | <b>2023</b>                        | <b>Receipt of royalties for intellectual property.</b><br>Wiley Blackwell : Other |
|                | <b>2024</b>                        | <b>Receipt of royalties for intellectual property.</b><br>Wiley Blackwell : Other |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                       | Type of Relationship with Industry |  |
|------------------------------|------------------------------------|--|
| Abreu Maria Manuela<br>Neves | <b>2023</b>                        | Nothing to be declared   |
|                              | <b>2024</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Lundbeck : Other  |
| Adamo Marianna               | <b>2023</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Edwards Lifesciences : Valvular Heart Disease<br>Abbott Vascular : Valvular Heart Disease   |
|                              | <b>2024</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Edwards Lifesciences : Valvular Heart Disease<br>Abbott Vascular : Valvular Heart Disease   |
| Agladze Rusudan              | <b>2023</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Astra Zeneca : Chronic Heart Failure<br>Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)  |
|                              | <b>2024</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Astra Zeneca : Chronic Heart Failure<br>Novartis : Chronic Heart Failure, Risk Factors and Prevention<br>Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)<br><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br>European Society of Cardiology : Training and Education |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert          | Type of Relationship with Industry  |
|-----------------|---|
| Arbelo Elena    | <b>2023</b><br><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>Marató TV3<br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Bayer : Atrial Fibrillation (AF)<br>Biosense Webster : Atrial Fibrillation (AF)  |
|                 | <b>2024</b><br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Boston Scientific : Arrhythmias, General<br>Bristol Myers Squibb : Myocardial Disease<br>Medtronic : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)<br><b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br>Chair of the EHRA Advocacy, Quality improvement and Health Economics Committee Member of the ESC Advocacy Committee |
| Asfalou Ilyasse | <b>2023</b><br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Novartis : Chronic Heart Failure, Hypertension<br>Merck Sharp & Dohme : Hypertension<br>Johnson & Johnson : Other<br>Novo-Nordisk : Risk Factors and Prevention<br><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br>Johnson & Johnson : Other   |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert             | Type of Relationship with Industry  |
|--------------------|---|
| Asfalou Ilyasse    | <p><b>2024</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Novartis : Chronic Heart Failure, Hypertension<br/> Astra Zeneca : Echocardiography, Cardiac Magnetic Resonance (CMR), Chronic Heart Failure<br/> Pfizer : Echocardiography, Cardiac Magnetic Resonance (CMR), Chronic Heart Failure, Myocardial Disease, European Society of Cardiology<br/> Boehringer-Ingelheim : Echocardiography, Chronic Heart Failure<br/> Merck Sharp &amp; Dohme : Hypertension<br/> Johnson &amp; Johnson : Other<br/> Abbott Laboratories : Risk Factors and Prevention<br/> Novo-Nordisk : Risk Factors and Prevention</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br/> Johnson &amp; Johnson : Other</p>   |
| Asselbergs Folkert | <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> EU Horizon<br/> The Dutch Research Council (NWO)<br/> The Netherlands Organisation for Health Research and Development (ZonMw)</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/> Novartis : Implementation of common data model for heart failure care pathway , principal investigator<br/> Astra Zeneca : Nudging trial to improve guideline adherence in heart failure, principal investigator</p> <hr/> <p><b>2024</b></p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/> Novartis : Data standardisation quality registry, principal investigator<br/> Astra Zeneca : Nudging trial to improve guideline adherence, principal investigator</p> |
| Banu Cristiana     | <p><b>2023</b></p> <p>Nothing to be declared</p>  |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                   | Type of Relationship with Industry |   |
|--------------------------|------------------------------------|---|
| Banu Cristiana           | <b>2024</b>                        | Nothing to be declared  |
| Bertelli Luca            | <b>2023</b>                        | Nothing to be declared  |
|                          | <b>2024</b>                        | Nothing to be declared  |
| Boriani Giuseppe         | <b>2023</b>                        | Nothing to be declared  |
|                          | <b>2024</b>                        | <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Bristol Myers Squibb : Arrhythmias, General<br/> Daiichi Sankyo : Atrial Fibrillation (AF)<br/> Boston Scientific : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/> Member of the Editorial Board of Acta Cardiologica and European Journal of Internal Medicine</p> |
| Bouزيد Mohammed El Amine | <b>2023</b>                        | Nothing to be declared  |
|                          | <b>2024</b>                        | Nothing to be declared  |
| Brida Margarita          | <b>2023</b>                        | Nothing to be declared  |
|                          | <b>2024</b>                        | Nothing to be declared  |
| Burke Noeleen            | <b>2023</b>                        | Nothing to be declared  |
|                          | <b>2024</b>                        | Nothing to be declared  |
| Byrne Robert             | <b>2023</b>                        | <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/> Biosensors : Clinical trial activity, Principal investigator<br/> Abbott Vascular : Research/educational grant to institution of employment to support fellowship programme, Clinical director<br/> Boston Scientific : Research/educational grant to institution of employment to support fellowship programme, Principal investigator<br/> Translumina : Research/educational grant to institution of employment to support research nurse for patient outcomes, Principal investigator</p>  |
|                          | <b>2024</b>                        | Nothing to be declared  |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert       | Type of Relationship with Industry  |
|--------------|---|
| Byrne Robert | <b>2023</b><br><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br>Member of Irish Heart Attack Audit Governance Committee Member Health Products Regulatory Authority (HPRA; Irish Competent Authority) Advisory Committee on Medical Devices<br><br><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br>Deputy Editor at EuroIntervention Guest Editor at Circulation  |
|              | <b>2024</b><br><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br>Biosensors : Clinical trial activity, Principal investigator<br>Boston Scientific : Research grant to institution of employment to support a clinical trial, Principal investigator<br>Abbott Vascular : Research/educational grant to institution of employment to support fellowship programme, Clinical director<br>Translumina : Research/educational grant to institution of employment to support research nurse for patient outcomes, Clinical director<br><br><b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br>Member of Irish Heart Attack Audit Governance Committee Member Health Products Regulatory Authority (HPRA; Irish Competent Authority) Advisory Committee on Medical Devices<br><br><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br>Deputy Editor at EuroIntervention Guest Editor at Circulation |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                | Type of Relationship with Industry  |
|-----------------------|---|
| Campuzano Ruiz Raquel | <p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b></p> <p>Amgen : Risk Factors and Prevention</p> <p>Astra Zeneca : Risk Factors and Prevention</p> <p>Bayer : Risk Factors and Prevention</p> <p>Daiichi Sankyo : Risk Factors and Prevention</p> <p>Novartis : Risk Factors and Prevention</p> <p>Servier : Risk Factors and Prevention</p> <p>Sanofi Aventis : Risk Factors and Prevention</p> <p>Menarini : Risk Factors and Prevention</p> <p>Lilly : Risk Factors and Prevention</p> <p>Ferrer Internacional : Risk Factors and Prevention</p> <p>Esteve : Risk Factors and Prevention</p> <p>Almirall Spain : Risk Factors and Prevention</p> <p>Novo-Nordisk : Risk Factors and Prevention</p> <p>Amarin : Risk Factors and Prevention</p> <p>Organon : Risk Factors and Prevention</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b></p> <p>Novartis : Risk Factors and Prevention</p> <p>Menarini : Risk Factors and Prevention</p> |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                | Type of Relationship with Industry  |
|-----------------------|---|
| Campuzano Ruiz Raquel | <p><b>2024</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b></p> <p>Amgen : Risk Factors and Prevention</p> <p>Astra Zeneca : Risk Factors and Prevention</p> <p>Daiichi Sankyo : Risk Factors and Prevention</p> <p>Novartis : Risk Factors and Prevention</p> <p>Servier : Risk Factors and Prevention</p> <p>Sanofi Aventis : Risk Factors and Prevention</p> <p>Esteve : Risk Factors and Prevention</p> <p>Almirall Spain : Risk Factors and Prevention</p> <p>Novo-Nordisk : Risk Factors and Prevention</p> <p>Amarin : Risk Factors and Prevention</p> <p>Viatis : Risk Factors and Prevention</p> <p>Organon : Risk Factors and Prevention</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b></p> <p>Novartis : Risk Factors and Prevention</p> |
| De Laval Ingrid       | <p><b>2023</b></p> <p>Nothing to be declared</p>  |
|                       | <p><b>2024</b></p> <p>Nothing to be declared</p>  |
| De Pauw Michel        | <p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b></p> <p>Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure</p>   |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert               | Type of Relationship with Industry |   |
|----------------------|------------------------------------|---|
| De Pauw Michel       | <b>2024</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure<br>Novo-Nordisk : Risk Factors and Prevention<br><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br>Astra Zeneca : Training and Education |
| Dritsas Athanasios   | <b>2023</b>                        | <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Novartis : Risk Factors and Prevention  |
|                      | <b>2024</b>                        | Nothing to be declared  |
| Einsfeld Lidia       | <b>2023</b>                        | Nothing to be declared  |
|                      | <b>2024</b>                        | Nothing to be declared  |
| El Ghalid Ahmed      | <b>2023</b>                        | <b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br>Member of Egyptian Society of cardiology (EgSC)   |
|                      | <b>2024</b>                        | <b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br>Member of Egyptian Society of cardiology (EgSC)  |
| Elezi Shpend         | <b>2023</b>                        | Nothing to be declared  |
|                      | <b>2024</b>                        | Nothing to be declared  |
| Ferhatbegovic Lamija | <b>2023</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Alkaloid : Arrhythmias, General  |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert               | Type of Relationship with Industry  |
|----------------------|---|
| Ferhatbegovic Lamija | <p><b>2024</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Alkaloid : Arrhythmias, General<br/> Novartis : Chronic Heart Failure<br/> Krka Pharma : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)<br/> Viatris : Hypertension<br/> Lek : Risk Factors and Prevention</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br/> Farmavita Sarajevo : Clinical Skills<br/> Abdi Ibrahim Pharmaceuticals : Clinical Skills<br/> Krka Pharma : Hypertension</p>  |
| Fras Zlatko          | <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> Slovenian National Research Agency</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Swixx Biopharma : Cardiovascular Disease in Special Populations<br/> Amgen : Risk Factors and Prevention<br/> Novartis : Risk Factors and Prevention<br/> Novo Nordisk : Risk Factors and Prevention</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/> Novartis : Clinical Studies HORIZON and VICTORION-2-P, PI</p> |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert           | Type of Relationship with Industry |   |
|------------------|------------------------------------|---|
| Fras Zlatko      | <b>2024</b>                        | <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>Slovenian National Research Agency</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Swixx Biopharma : Cardiovascular Disease in Special Populations<br/>Amgen : Risk Factors and Prevention<br/>Novartis : Risk Factors and Prevention<br/>Novo Nordisk : Risk Factors and Prevention</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/>Novartis : Clinical Studies HORIZON and VICTORION-2-P, PI</p> |
| Frigoli Enrico   | <b>2023</b>                        | <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>Cardiocentro Ticino Institute - Ente Ospedaliero Cantonale, Lugano, Switzerland</p>  |
|                  | <b>2024</b>                        | <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>Cardiocentro Ticino Institute - Ente Ospedaliero Cantonale, Lugano, Switzerland</p>   |
| Galiuto Leonarda | <b>2023</b>                        | Nothing to be declared  |
|                  | <b>2024</b>                        | Nothing to be declared  |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert              | Type of Relationship with Industry  |
|---------------------|---|
| Gandjbakhch Estelle | <p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>           Boston Scientific : Device Therapy<br/>           Medtronic : Device Therapy<br/>           Biotronik : Device Therapy<br/>           Microport : Device Therapy<br/>           Abbott : Interventional Cardiology</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/>           Biotronik : research grant for academic research on inherited arrhythmia and catheter ablation, investigator<br/>           Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator<br/>           Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator<br/>           Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator</p>   |
|                     | <p><b>2024</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>           Boston Scientific : Device Therapy<br/>           Medtronic : Device Therapy<br/>           Biotronik : Device Therapy<br/>           Zoll Medical : Device Therapy<br/>           Microport : Device Therapy<br/>           Abbott : Interventional Cardiology<br/>           Tenaya : Myocardial Disease</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/>           Biotronik : research grant for academic research on inherited arrhythmia and catheter ablation, investigator<br/>           Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator<br/>           Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator<br/>           Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator</p> |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert         | Type of Relationship with Industry |  |
|----------------|------------------------------------|--|
| Grace Sherry   | <b>2023</b>                        | <b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br>International Council of Cardiovascular Prevention and Rehabilitation  |
|                | <b>2024</b>                        | <b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br>International Council of Cardiovascular Prevention and Rehabilitation   |
| Grand Johannes | <b>2023</b>                        | <b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br>Board member of Danish Younger cardiologists   |
|                | <b>2024</b>                        | <b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>The Alfred Benzon Foundation □ C/O Rigshospitalet – Copenhagen University Hospital   |
| Gungor Baris   | <b>2023</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Novartis : Chronic Heart Failure<br>Menarini : Risk Factors and Prevention  |
|                | <b>2024</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Recordati International : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)<br>Biotronik : Device Therapy<br>Merck Sharp & Dohme : Risk Factors and Prevention<br><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br>Menarini : European Society of Cardiology |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert             | Type of Relationship with Industry  |
|--------------------|---|
| Heidecker Bettina  | <b>2023</b><br><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>Pfizer<br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Pfizer, Bayer, Sanofi-Aventis, Novartis, Astra Zeneca : Clinical Skills, Chronic Heart Failure, Acute Heart Failure, Myocardial Disease, Pericardial Disease<br><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br>Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator |
|                    | <b>2024</b><br><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>Pfizer<br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Pfizer, Bayer, Sanofi-Aventis, Novartis, Astra Zeneca : Clinical Skills , Chronic Heart Failure , Acute Heart Failure , Myocardial Disease , Pericardial Disease<br><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br>Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator  |
| Heldner Mirjam     | <b>2023</b><br>Nothing to be declared   |
|                    | <b>2024</b><br>Nothing to be declared   |
| Helmark Charlotte  | <b>2023</b><br>Nothing to be declared   |
|                    | <b>2024</b><br>Nothing to be declared   |
| Hemmat Gaber Marwa | <b>2023</b><br>Nothing to be declared   |
|                    | <b>2024</b><br>Nothing to be declared   |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                    | Type of Relationship with Industry  |
|---------------------------|---|
| Hermann Matthias          | <b>2023</b><br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Boehringer Ingelheim Schweiz : Chronic Heart Failure<br><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br>Daiichi Sankyo : co-funding aging cohort, PI<br>Novartis : co-funding aging cohort, PI<br>Novo-Nordisk : co-funding aging cohort, PI<br>Roche Diagnostics : co-funding aging cohort, PI               |
|                           | <b>2024</b><br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Boehringer Ingelheim Schweiz : Chronic Heart Failure<br><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br>Daiichi Sankyo : co-funding aging cohort, PI<br>Novartis : co-funding aging cohort, PI<br>Novo-Nordisk : co-funding aging cohort, PI<br>Roche Diagnostics : co-funding aging cohort, PI               |
| Herrmann-Lingen Christoph | <b>2023</b><br><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>European Commission<br>German Ministry of Education and Research<br>German Research Foundation<br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Novartis : Risk Factors and Prevention<br><b>Receipt of royalties for intellectual property.</b><br>Hogrefe Publishers : Other |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                    | Type of Relationship with Industry   |
|---------------------------|--|
| Herrmann-Lingen Christoph | <b>2023</b><br><b>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b><br>Healthcare - Other - stock option<br>Education - Honoraria for educational courses sponsored by German cardiac society<br><br><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br>German Heart Foundation<br><br><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br>Active membership in societies of cardiology and psychosomatic medicine   |
|                           | <b>2024</b><br><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>European Commission<br>German Ministry of Education and Research<br>German Research Foundation<br><br><b>Receipt of royalties for intellectual property.</b><br>Springer publishing house : Clinical Skills<br>Hogrefe Publishers : Other<br><br><b>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b><br>Healthcare - Other - stock option<br>Education - Honoraria for educational lectures or courses sponsored by German cardiac society, Auditorium publishers or various hospitals, respectively<br><br><b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br>German Heart Foundation<br><br><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br>Active membership in societies of cardiology and psychosomatic medicine |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert           | Type of Relationship with Industry  |
|------------------|---|
| Hill Loreena     | <b>2023</b><br><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>British Heart Foundation Fellowship<br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Astra Zeneca : Chronic Heart Failure<br>Medtronic : Chronic Heart Failure   |
|                  | <b>2024</b><br><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>British Heart Foundation Fellowship<br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Astra Zeneca : Chronic Heart Failure<br>Medtronic : Device Therapy, Chronic Heart Failure<br>Alnylam : Other   |
| Hlebowicz Joanna | <b>2023</b><br><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>Jane and Dan Olsson Foundation for Scientific Purposes, Anna-Lisa and Sven Eric Lundgren Foundation for Medical Research.<br>The Heart-Lung Foundation, Mats Kleberg Foundation, Thorsten Westerström Foundation, The Heart Children Foundation, HeartLung, Regional research support, Greta and Johan Kock Foundations, SUS funds<br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Amgen Inc : Research Methodology |
|                  | <b>2024</b><br><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>Jane and Dan Olsson Foundation for Scientific Purposes, Anna-Lisa and Sven Eric Lundgren Foundation for Medical Research.<br>The Heart-Lung Foundation, Mats Kleberg Foundation, Thorsten Westerström Foundation, The Heart Children Foundation, HeartLung, Regional research support, Greta and Johan Kock Foundations, SUS funds   |
| Hynes Lisa       | <b>2023</b><br><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br>Heart & Stroke Voice Ireland which is a patient advocacy group is an initiative within Croí, the organisation I work for.  |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert       | Type of Relationship with Industry   |
|--------------|--|
| Hynes Lisa   | <b>2024</b><br><b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br>Heart & Stroke Voice Ireland which is a patient advocacy group is an initiative within Croí, the organisation I work for.  |
| Ibanez Borja | <b>2023</b><br><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br>My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomía, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).   |
|              | <b>2024</b><br><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br>My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomía, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).   |
| Irs Alar     | <b>2023</b><br><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br>Abbott : Acute Cardiac Care<br><br><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br>Abbott : Quality registry Euroheart, national activities, national coordinator<br>Medtronic : Quality registry Euroheart, national activities, national coordinator<br>Novartis : Quality registry Euroheart, national activities, national coordinator<br><br><b>Employment (including part time) in healthcare industry during the year for which you are declaring.</b><br>Estonian State Agency of Medicines (national regulatory agency for pharmaceutical products) : Chief Medical Officer<br><br><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br>Estonian Society of Cardiology, Board Member |
|              | <b>2024</b><br><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br>Abbott : Interventional Cardiology<br>Boston Scientific : Interventional Cardiology<br>Medtronic : Interventional Cardiology   |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert       | Type of Relationship with Industry  |
|--------------|---|
| Irs Alar     | <p><b>2024</b></p> <p><b>Employment (including part time) in healthcare industry.</b><br/>Estonian State Agency of Medicines (national regulatory agency for pharmaceutical products) : Chief Medical Officer</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br/>Estonian Society of Cardiology, Board Member June 2018 - June 2024.</p>  |
| James Stefan | <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>Wallenberg foundation, Swedish heart and lung foundation</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Medtronic : Valvular Heart Disease</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/>Elixir : clinical trial, study chair<br/>MSD : Clinical trial, trial executive committee<br/>Amgen : Executive committee member, Executive committee member<br/>Janssen-Cilag : Executive committee member, Executive committee member<br/>Astra Zeneca : Study PI , Principal investigator</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br/>Swedish medical Association, Swedish cardiac society</p> |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                    | Type of Relationship with Industry   |
|---------------------------|--|
| James Stefan              | <p><b>2024</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>Swedish research council</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Edwards Lifesciences : Valvular Heart Disease<br/>Medtronic : Valvular Heart Disease</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/>Amgen Inc : Clinical trial, Executive committee<br/>Merck Sharp &amp; Dohme : Clinical trial, Executive committee<br/>New Amsterdam : DSMB committee. Lipid management , DSMB committee<br/>Janssen-Cilag : Executive committee, Executive committee</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br/>Board member of the Swedish research council</p> |
| Karamfiloff Kiril         | <p><b>2023</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2024</b></p> <p>Nothing to be declared</p>  |
| Karimli Emin              | <p><b>2023</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2024</b></p> <p>Nothing to be declared</p>  |
| Karlsson Hrobjartur Darri | <p><b>2023</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2024</b></p> <p>Nothing to be declared</p>  |
| Katreniakova Zuzana       | <p><b>2023</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2024</b></p> <p>Nothing to be declared</p>  |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert              | Type of Relationship with Industry   |
|---------------------|--|
| Kharlamov Alexander | <b>2023</b><br><b>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b><br>Healthcare - Clinical Skills , Echocardiography , Cardiac Computed Tomography (CT) , Cardiac Magnetic Resonance (CMR) , Nuclear Imaging , Hybrid and Fusion Imaging , Cross-Modality and Multi-Modality Imaging Topics , Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) , Interventional Cardiology , e-Cardiology/Digital Health , Public Health and Health Economics - The main business target of DHRF and personal interest is an advanced cardiovascular imaging and related research service. |
|                     | <b>2024</b><br><b>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b><br>Healthcare - Clinical Skills , Echocardiography , Cardiac Computed Tomography (CT) , Cardiac Magnetic Resonance (CMR) , Nuclear Imaging , Hybrid and Fusion Imaging , Cross-Modality and Multi-Modality Imaging Topics , Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) , Interventional Cardiology , e-Cardiology/Digital Health , Public Health and Health Economics - The main business target of DHRF and personal interest is an advanced cardiovascular imaging and related research service. |
| Kindermans Hanne    | <b>2023</b><br><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br>Non-conflicting but for the sake of transparency I am involved in the EU-funded Horizon 2020 Coroprevention project since 2019.  |
|                     | <b>2024</b><br><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br>Non-conflicting but for the sake of transparency I am involved in the EU-funded Horizon 2020 Coroprevention project since 2019.  |
| Kober Lars          | <b>2023</b><br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Astra Zeneca : Chronic Heart Failure<br>Boehringer-Ingelheim : Chronic Heart Failure<br>Novartis : Chronic Heart Failure<br>Novo-Nordisk : Chronic Heart Failure   |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                | Type of Relationship with Industry |  |
|-----------------------|------------------------------------|--|
| Kober Lars            | <b>2024</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Astra Zeneca : Chronic Heart Failure<br>Boehringer-Ingelheim : Chronic Heart Failure<br>Novartis : Chronic Heart Failure<br>Novo-Nordisk : Chronic Heart Failure  |
| Koskinas Konstantinos | <b>2023</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Amgen : Risk Factors and Prevention<br>Daiichi Sankyo : Risk Factors and Prevention<br>Sanofi Aventis : Risk Factors and Prevention   |
|                       | <b>2024</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Sanofi Aventis : Risk Factors and Prevention<br>Merck Sharp & Dohme : Risk Factors and Prevention<br><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Daiichi Sankyo : Risk Factors and Prevention<br>Sanofi Aventis : Risk Factors and Prevention |
| Kostov Jorgo          | <b>2023</b>                        | Nothing to be declared   |
|                       | <b>2024</b>                        | Nothing to be declared   |
| Kuijpers Petra        | <b>2023</b>                        | Nothing to be declared   |
|                       | <b>2024</b>                        | Nothing to be declared   |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert         | Type of Relationship with Industry   |
|----------------|--|
| Landmesser Ulf | <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> German Center of Cardiovascular Research (DZHK)</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)<br/> Amgen : Risk Factors and Prevention<br/> Novartis : Risk Factors and Prevention<br/> Sanofi Aventis : Risk Factors and Prevention</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/> Abbott : EXAMINE-CAD Study, Principal Investigator<br/> Novartis : Support of clinical study to institution, Principal investigator</p>   |
|                | <p><b>2024</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> German Center of Cardiovascular Research (DZHK)<br/> Leducq Foundation - Network of excellence in cardiovascular research</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)<br/> Amgen : Risk Factors and Prevention<br/> Novartis : Risk Factors and Prevention<br/> Sanofi Aventis : Risk Factors and Prevention</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/> Abbott : Clinical Study, Principal Investigator<br/> Merck Sharp &amp; Dohme : Clinical Study, Steering Committee<br/> Novartis : Support of clinical study to institution, Principal investigator</p> |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                | Type of Relationship with Industry |   |
|-----------------------|------------------------------------|---|
| Lapinskas Tomas       | <b>2023</b>                        | <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>Lithuanian Research Council</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br/>Member of SCMR Advocacy group.</p>   |
|                       | <b>2024</b>                        | <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>Lithuanian Research Council</p>   |
| Lecic-Tosevski Dusica | <b>2023</b>                        | Nothing to be declared  |
|                       | <b>2024</b>                        | Nothing to be declared  |
| Lip Gregory Yh        | <b>2023</b>                        | <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/>Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator</p> <p>Anthos : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/>Shares in private limited company (a legal separate entity in UK), but no salary/income/personal remuneration received.</p> |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                 | Type of Relationship with Industry   |
|------------------------|--|
| Lip Gregory Yh         | <p><b>2024</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Pfizer : Atrial Fibrillation (AF)<br/>Bristol Myers Squibb : Atrial Fibrillation (AF)</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br/>Daiichi Sankyo : Atrial Fibrillation (AF)</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/>Bristol Myers Squibb : AF 'real world' registry work. Academic, non promotional research work on registries , project supervision<br/>Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellows., project supervision<br/>Anthos : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellows., project supervision</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/>Editorial roles in a number of academic journals. Shares in private limited company (a legal separate entity in UK), but no salary/income/personal remuneration received.</p> |
| Magavern Emma          | <p><b>2023</b> Nothing to be declared</p> <p><b>2024</b> Nothing to be declared</p>  |
| Makhkamova Nargiza     | <p><b>2023</b> Nothing to be declared</p> <p><b>2024</b> Nothing to be declared</p>  |
| Mattioli Anna Vittoria | <p><b>2023</b> Nothing to be declared</p> <p><b>2024</b> Nothing to be declared</p>  |
| Mcevoy John William    | <p><b>2023</b> Nothing to be declared</p> <p><b>2024</b> Nothing to be declared</p>  |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert              | Type of Relationship with Industry |  |
|---------------------|------------------------------------|--|
| McGreavy Paul       | <b>2023</b>                        | <b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br>Global Heart Hub : Other<br><br><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br>ESC Patient Forum Global Heart Hub                  |
|                     | <b>2024</b>                        | <b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br>ESC Patient Forum Global Heart Hub - Associate  |
| Mierzynska Anna     | <b>2023</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Medtronic : Cardiovascular Nursing and Allied Professions   |
|                     | <b>2024</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Medtronic : Cardiovascular Nursing and Allied Professions   |
| Mihaylova Borislava | <b>2023</b>                        | <b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>Barts Charity, UK<br>Bowel Research UK<br>Cancer Research UK<br>National Institute for Health and Care Research, UK |
|                     | <b>2024</b>                        | <b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>Barts Charity, UK<br>Bowel Research UK<br>Cancer Research UK<br>National Institute for Health and Care Research, UK  |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert            | Type of Relationship with Industry  |
|-------------------|---|
| Mintale Iveta     | <b>2023</b><br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Bayer : Atrial Fibrillation (AF)<br>Astra Zeneca : Chronic Heart Failure<br>Servier : Hypertension, Risk Factors and Prevention<br>Berlin Chemie AG : Myocardial Disease<br>Novo-Nordisk : Risk Factors and Prevention  |
|                   | <b>2024</b><br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Bayer : Atrial Fibrillation (AF)<br>Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)<br>Servier : Hypertension, Risk Factors and Prevention<br>Berlin Chemie AG : Myocardial Disease   |
| Mirrakhimov Erkin | <b>2023</b><br>Nothing to be declared   |
|                   | <b>2024</b><br>Nothing to be declared   |
| Mitu Florin       | <b>2023</b><br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Servier : Hypertension<br>Zentiva : Hypertension<br>Sanofi Aventis : Pharmacology and Pharmacotherapy<br>Pfizer : Risk Factors and Prevention, Pharmacology and Pharmacotherapy<br><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br>Sanofi Aventis : Pharmacology and Pharmacotherapy |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                   | Type of Relationship with Industry  |
|--------------------------|---|
| Mitu Florin              | <p><b>2024</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Servier : Hypertension<br/> Zentiva : Hypertension<br/> Sanofi Aventis : Pharmacology and Pharmacotherapy<br/> Pfizer : Risk Factors and Prevention, Pharmacology and Pharmacotherapy</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br/> Sanofi Aventis : Pharmacology and Pharmacotherapy</p>  |
| Moelgaard Inge           | <p><b>2023</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2024</b></p> <p>Nothing to be declared</p>   |
| Monsuez Jean-Jacques     | <p><b>2023</b></p> <p><b>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b><br/> Education - Editor in chief Archives des maladies du coeur et des vaisseaux pratiques, CME journal of the French society of cardiology</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/> Editor in chief Archives des maladies du coeur et des vaisseaux, CME journal of the French society of cardiology</p> <hr/> <p><b>2024</b></p> <p><b>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b><br/> Education - Editor in chief Archives des maladies du coeur et des vaisseaux pratiques, CME journal of the French society of cardiology</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/> Editor in chief Archives des maladies du coeur et des vaisseaux, CME journal of the French society of cardiology</p> |
| Moutiris Joseph Antoniou | <p><b>2023</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2024</b></p> <p>Nothing to be declared</p>   |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert               | Type of Relationship with Industry |   |
|----------------------|------------------------------------|---|
| Nardi Agmon Inbar    | <b>2023</b>                        | <b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>Gassner Fund for Medical Research  |
|                      | <b>2024</b>                        | <b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>Israel Cancer Association   |
| Nielsen Jens Cosedis | <b>2023</b>                        | Nothing to be declared  |
|                      | <b>2024</b>                        | Nothing to be declared  |
| Pasquet Agnes A      | <b>2023</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Servier : Hypertension<br><br><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Servier : Hypertension<br><br><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br>Philips : echography, contribution and support |
|                      | <b>2024</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Servier : Hypertension<br><br><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Servier : Hypertension<br><br><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br>Philips : echography, contribution and support |
| Prescott Eva         | <b>2023</b>                        | Nothing to be declared  |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert          | Type of Relationship with Industry |   |
|-----------------|------------------------------------|---|
| Prescott Eva    | <b>2024</b>                        | Nothing to be declared  |
| Rakisheva Amina | <b>2023</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Astra Zeneca : Chronic Heart Failure<br>Novartis : Chronic Heart Failure<br>Roche Diagnostics : Chronic Heart Failure  |
|                 | <b>2024</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Astra Zeneca : Chronic Heart Failure<br>Boehringer-Ingelheim : Chronic Heart Failure   |
| Revenco Valeriu | <b>2023</b>                        | Nothing to be declared  |
|                 | <b>2024</b>                        | Nothing to be declared  |
| Rice Eva        | <b>2023</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Bayer : Chronic Heart Failure<br>Novartis : Chronic Heart Failure<br>Orion : Chronic Heart Failure<br>Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)<br><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert             | Type of Relationship with Industry  |
|--------------------|---|
| Rice Eva           | <p><b>2024</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Astra Zeneca : Chronic Heart Failure<br/> Bayer : Chronic Heart Failure<br/> Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> MSD : Risk Factors and Prevention</p>  |
| Rickovic Valentina | <p><b>2023</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2024</b></p> <p>Nothing to be declared</p>   |
| Rocca Bianca       | <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> Cancer UK</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Aboca, SRL : Other</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/> Editorial Board of: Assistant Editor Diabetes and Vascular Disease Research Advisory Board: Pharmadvances. Associate Editor: Cardiovascular Drugs and Therapy, Clinical Pharmacology Editorial Board: Bleeding, Thrombosis, and Vascular Biology Associate Editor. Frontiers in Drug Safety and Regulation Section on Cardiovascular Drug Safety Associate Editor for European Cardiology Review Editorial Board European Journal of Preventive Cardiology Editorial Board Journal of Thrombosis and Thrombolysis Editorial Board International Journal of Cardiology</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                    | Type of Relationship with Industry  |
|---------------------------|---|
| Rocca Bianca              | <p><b>2024</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>Cancer UK</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Bayer AG : Pharmacology and Pharmacotherapy</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/>Bios Therapy : Substance Based medical devices in obesity, site investigator</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br/>ISTH, Italian Society of Thrombosis and Haemostasis (SISTE), italian society of Pharmacology (SIF), Mediterranean League against Thrombosis</p> |
| Rossello Francisco Javier | <p><b>2023</b></p> <p>Nothing to be declared</p> <p><b>2024</b></p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/>Associate editor of Heart - <a href="https://heart.bmj.com/pages/editorial-board">https://heart.bmj.com/pages/editorial-board</a> Associate Statistical Editor of Circulation: Cardiovascular Quality and Outcomes - <a href="https://www.ahajournals.org/circoutcomes/editorial-board">https://www.ahajournals.org/circoutcomes/editorial-board</a></p>   |
| Salzwedel Annett          | <p><b>2023</b></p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br/>German Association of Prevention and Rehabilitation of Cardiovascular Diseases</p> <p><b>2024</b></p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br/>German Association of Prevention and Rehabilitation of Cardiovascular Diseases</p>  |
| Sannino Anna              | <p><b>2023</b></p> <p>Nothing to be declared</p> <p><b>2024</b></p> <p>Nothing to be declared</p>   |
| Shantsila Eduard          | <p><b>2023</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>MediWhale (South Korea) : Other</p> <p><b>2024</b></p> <p>Nothing to be declared</p>   |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                | Type of Relationship with Industry |  |
|-----------------------|------------------------------------|--|
| Sirenko Yuriy         | <b>2023</b>                        | Nothing to be declared   |
|                       | <b>2024</b>                        | Nothing to be declared   |
| Ski Chantal           | <b>2023</b>                        | Nothing to be declared   |
|                       | <b>2024</b>                        | Nothing to be declared   |
| Steptoe Andrew        | <b>2023</b>                        | Nothing to be declared   |
|                       | <b>2024</b>                        | Nothing to be declared   |
| Tanner Felix C        | <b>2023</b>                        | <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> Swiss Heart Foundation</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br/> Philips : Echocardiography</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/> Secretary, UEMS Cardiac Section Board, Swiss Institute for Medical Education Board, Swiss Heart Foundation Editorial Board, International Journal of Cardiology Editorial Board, Journal of Clinical Medicine Editorial Board, Swiss Medical Weekly Editorial Board, Cardiovascular Medicine</p> |
|                       | <b>2024</b>                        | <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> Swiss Heart Foundation</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/> Secretary, UEMS Cardiac Section Board, Swiss Institute for Medical Education Board, Swiss Heart Foundation Editorial Board, International Journal of Cardiology Editorial Board, Journal of Clinical Medicine Editorial Board, Swiss Medical Weekly</p>  |
| Telles Correia Diogo  | <b>2023</b>                        | Nothing to be declared   |
|                       | <b>2024</b>                        | Nothing to be declared   |
| Tundybayeva Meiramgul | <b>2023</b>                        | Nothing to be declared   |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                | Type of Relationship with Industry |  |
|-----------------------|------------------------------------|--|
| Tundybayeva Meiramgul | <b>2024</b>                        | Nothing to be declared   |
| Vaartjes Ilonca       | <b>2023</b>                        | Nothing to be declared   |
|                       | <b>2024</b>                        | Nothing to be declared   |
| von Kemp Berlinde     | <b>2023</b>                        | Nothing to be declared   |
|                       | <b>2024</b>                        | Nothing to be declared   |
| Vranckx Pascal        | <b>2023</b>                        | Nothing to be declared   |
|                       | <b>2024</b>                        | <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>CSL Behring : Acute Coronary Syndromes<br>Janssen-Bristol Myers Squibb alliance : Acute Coronary Syndromes  |
| Vrints Christiaan J M | <b>2023</b>                        | Nothing to be declared   |
|                       | <b>2024</b>                        | Nothing to be declared   |
| Zeppenfeld Katja      | <b>2023</b>                        | <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)<br><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br>Biosense Webster : Investigator initiated research, ventricular arrhythmias, PI |
|                       | <b>2024</b>                        | Nothing to be declared   |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                   | Type of Relationship with Industry   |
|--------------------------|--|
| Zima Endre               | <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>TKP 2021 – NVA-12</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Innomed : Arrhythmias, General, Ventricular Arrhythmias and Sudden Cardiac Death (SCD), Training and Education<br/>Astra Zeneca : Atrial Fibrillation (AF), Chronic Heart Failure<br/>Abbott : Device Therapy<br/>Biotronik : Syncope and Bradycardia , Ventricular Arrhythmias and Sudden Cardiac Death (SCD) , Device Therapy , Chronic Heart Failure , e-Cardiology/Digital Health , Public Health and Health Economics , Training and Education<br/>Medtronic : Syncope and Bradycardia , Ventricular Arrhythmias and Sudden Cardiac Death (SCD) , Device Therapy , Chronic Heart Failure , Valvular Heart Disease<br/>Boston Scientific : Syncope and Bradycardia, Ventricular Arrhythmias and Sudden Cardiac Death (SCD), Device Therapy, Chronic Heart Failure</p> |
|                          | <p><b>2024</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>TKP 2021 – NVA-12</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Innomed : Arrhythmias, General, Ventricular Arrhythmias and Sudden Cardiac Death (SCD), Training and Education<br/>Astra Zeneca : Atrial Fibrillation (AF), Chronic Heart Failure<br/>Abbott : Device Therapy<br/>Biotronik : Syncope and Bradycardia , Ventricular Arrhythmias and Sudden Cardiac Death (SCD) , Device Therapy , Chronic Heart Failure , e-Cardiology/Digital Health , Public Health and Health Economics , Training and Education<br/>Medtronic : Syncope and Bradycardia , Ventricular Arrhythmias and Sudden Cardiac Death (SCD) , Device Therapy , Chronic Heart Failure , Valvular Heart Disease<br/>Boston Scientific : Syncope and Bradycardia, Ventricular Arrhythmias and Sudden Cardiac Death (SCD), Device Therapy, Chronic Heart Failure</p>  |
| Zwisler Ann-Dorthe Olsen | <p><b>2023</b></p> <p>Nothing to be declared</p>   |

## 2025 Clinical Consensus Statement on mental health and CVD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                   | Type of Relationship with Industry  |
|--------------------------|---|
| Zwisler Ann-Dorthe Olsen | <b>2024</b><br><b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br>Danish Society of Cardiology Danish Society of Palliative Medicine Danish Society of mulitmorbidty and polypharmacy |

## Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert             | Type of Relationship with Industry  |
|--------------------|---|
| Adamo Marianna     | <b>2023</b> <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Edwards Lifesciences : Valvular Heart Disease<br>Abbott Vascular : Valvular Heart Disease  |
|                    | <b>2024</b> <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Edwards Lifesciences : Valvular Heart Disease<br>Abbott Vascular : Valvular Heart Disease  |
| Aktaa Suleman      | <b>2023</b> Nothing to be declared  |
|                    | <b>2024</b> Nothing to be declared  |
| Asselbergs Folkert | <b>2023</b> <b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>EU Horizon<br>The Dutch Research Council (NWO)<br>The Netherlands Organisation for Health Research and Development (ZonMw)<br><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br>Novartis : Implementation of common data model for heart failure care pathway , principal investigator<br>Astra Zeneca : Nudging trial to improve guideline adherence in heart failure, principal investigator |
|                    | <b>2024</b> <b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br>Novartis : Data standardisation quality registry, principal investigator<br>Astra Zeneca : Nudging trial to improve guideline adherence, principal investigator   |
| Baigent Colin      | <b>2023</b> <b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>UK Medical Research Council<br><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br>Boehringer-Ingelheim : Funding provided for the coordination of the EMPA-KIDNEY trial, Chair of Steering Committee  |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert           | Type of Relationship with Industry  |
|------------------|---|
| Baigent Colin    | <p><b>2024</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>UK Medical Research Council</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/>Boehringer-Ingelheim : Funding provided for the coordination of the EMPA-KIDNEY and EASI-KIDNEY trials, Chair of Steering Committee</p>  |
| Borger Michael A | <p><b>2023</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Artivion (formerly CryoLife) : Diseases of the Aorta<br/>Abbott : Valvular Heart Disease<br/>Edwards Lifesciences : Valvular Heart Disease<br/>Medtronic : Valvular Heart Disease</p> <p><b>2024</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Artivion (formerly CryoLife) : Diseases of the Aorta<br/>Abbott : Valvular Heart Disease<br/>Edwards Lifesciences : Valvular Heart Disease<br/>Medtronic : Valvular Heart Disease</p> |
| Boriani Giuseppe | <p><b>2023</b></p> <p>Nothing to be declared</p> <p><b>2024</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Bristol Myers Squibb : Arrhythmias, General<br/>Daiichi Sankyo : Atrial Fibrillation (AF)<br/>Boston Scientific : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p>   |

## Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert           | Type of Relationship with Industry |  |
|------------------|------------------------------------|--|
| Boriani Giuseppe | <b>2024</b>                        | <b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br>Member of the Editorial Board of Acta Cardiologica and European Journal of Internal Medicine  |
| Brida Margarita  | <b>2023</b>                        | Nothing to be declared   |
|                  | <b>2024</b>                        | Nothing to be declared   |
| Byrne Robert     | <b>2023</b>                        | <b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br>Biosensors : Clinical trial activity, Principal investigator<br>Abbott Vascular : Research/educational grant to institution of employment to support fellowship programme, Clinical director<br>Boston Scientific : Research/educational grant to institution of employment to support fellowship programme, Principal investigator<br>Translumina : Research/educational grant to institution of employment to support research nurse for patient outcomes, Principal investigator<br><br><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br>Member of Irish Heart Attack Audit Governance Committee Member Health Products Regulatory Authority (HPRA; Irish Competent Authority) Advisory Committee on Medical Devices<br><br><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br>Deputy Editor at EuroIntervention Guest Editor at Circulation |
|                  | <b>2024</b>                        | <b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br>Biosensors : Clinical trial activity, Principal investigator<br>Boston Scientific : Research grant to institution of employment to support a clinical trial, Principal investigator<br>Abbott Vascular : Research/educational grant to institution of employment to support fellowship programme, Clinical director<br>Translumina : Research/educational grant to institution of employment to support research nurse for patient outcomes, Clinical director   |

## Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert              | Type of Relationship with Industry   |
|---------------------|--|
| Byrne Robert        | <p><b>2024</b></p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br/>Member of Irish Heart Attack Audit Governance Committee Member Health Products Regulatory Authority (HPRA; Irish Competent Authority) Advisory Committee on Medical Devices</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/>Deputy Editor at EuroIntervention Guest Editor at Circulation</p>   |
| Gandjbakhch Estelle | <p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Boston Scientific : Device Therapy<br/>Medtronic : Device Therapy<br/>Biotronik : Device Therapy<br/>Microport : Device Therapy<br/>Abbott : Interventional Cardiology</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/>Biotronik : research grant for academic research on inherited arrhythmia and catheter ablation, investigator<br/>Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator<br/>Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator<br/>Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator</p> |

## Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert              | Type of Relationship with Industry  |
|---------------------|---|
| Gandjbakhch Estelle | <p><b>2024</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Boston Scientific : Device Therapy<br/> Medtronic : Device Therapy<br/> Biotronik : Device Therapy<br/> Zoll Medical : Device Therapy<br/> Microport : Device Therapy<br/> Abbott : Interventional Cardiology<br/> Tenaya : Myocardial Disease</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/> Biotronik : research grant for academic research on inherited arrhythmia and catheter ablation, investigator<br/> Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator<br/> Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator<br/> Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator</p> |
| Heidecker Bettina   | <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> Pfizer</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Pfizer, Bayer, Sanofi-Aventis, Novartis, Astra Zeneca : Clinical Skills, Chronic Heart Failure, Acute Heart Failure, Myocardial Disease, Pericardial Disease</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/> Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator</p>  |

## Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert            | Type of Relationship with Industry  |
|-------------------|---|
| Heidecker Bettina | <p><b>2024</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>Pfizer</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Pfizer, Bayer, Sanofi-Aventis, Novartis, Astra Zeneca : Clinical Skills , Chronic Heart Failure , Acute Heart Failure , Myocardial Disease , Pericardial Disease</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/>Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator</p>  |
| Hennemuth Anja    | <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>BMBF<br/>Deutsche Forschungsgemeinschaft</p> <p><b>2024</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>BMBF<br/>Deutsche Forschungsgemeinschaft</p>  |
| Ibanez Borja      | <p><b>2023</b></p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/>My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p> <p><b>2024</b></p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/>My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p> |

## Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert       | Type of Relationship with Industry  |
|--------------|---|
| James Stefan | <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>Wallenberg foundation, Swedish heart and lung foundation</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Medtronic : Valvular Heart Disease</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/>Elixir : clinical trial, study chair<br/>MSD : Clinical trial, trial executive committee<br/>Amgen : Executive committee member, Executive committee member<br/>Janssen-Cilag : Executive committee member, Executive committee member<br/>Astra Zeneca : Study PI , Principal investigator</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b><br/>Swedish medical Association, Swedish cardiac society</p> |
|              | <p><b>2024</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>Swedish research council</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Edwards Lifesciences : Valvular Heart Disease<br/>Medtronic : Valvular Heart Disease</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/>Amgen Inc : Clinical trial, Executive committee<br/>Merck Sharp &amp; Dohme : Clinical trial, Executive committee<br/>New Amsterdam : DSMB committee. Lipid management , DSMB committee<br/>Janssen-Cilag : Executive committee, Executive committee</p>  |

## Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert         | Type of Relationship with Industry |  |
|----------------|------------------------------------|--|
| James Stefan   | <b>2024</b>                        | <b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br>Board member of the Swedish research council  |
| Juni Peter     | <b>2023</b>                        | Nothing to be declared   |
|                | <b>2024</b>                        | Nothing to be declared   |
| Landmesser Ulf | <b>2023</b>                        | <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>German Center of Cardiovascular Research (DZHK)</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)<br/>Amgen : Risk Factors and Prevention<br/>Novartis : Risk Factors and Prevention<br/>Sanofi Aventis : Risk Factors and Prevention</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/>Abbott : EXAMINE-CAD Study, Principal Investigator<br/>Novartis : Support of clinical study to institution, Principal investigator</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert         | Type of Relationship with Industry   |
|----------------|--|
| Landmesser Ulf | <p><b>2024</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> German Center of Cardiovascular Research (DZHK)<br/> Leducq Foundation - Network of excellence in cardiovascular research</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/> Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)<br/> Amgen : Risk Factors and Prevention<br/> Novartis : Risk Factors and Prevention<br/> Sanofi Aventis : Risk Factors and Prevention</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/> Abbott : Clinical Study, Principal Investigator<br/> Merck Sharp &amp; Dohme : Clinical Study, Steering Committee<br/> Novartis : Support of clinical study to institution, Principal investigator</p> |
| Lip Gregory Yh | <p><b>2023</b></p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/> Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator<br/> Anthos : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/> Shares in private limited company (a legal separate entity in UK), but no salary/income/personal remuneration received.</p>   |

## Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert              | Type of Relationship with Industry   |
|---------------------|--|
| Lip Gregory Yh      | <p><b>2024</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Pfizer : Atrial Fibrillation (AF)<br/>Bristol Myers Squibb : Atrial Fibrillation (AF)</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br/>Daiichi Sankyo : Atrial Fibrillation (AF)</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/>Bristol Myers Squibb : AF 'real world' registry work. Academic, non promotional research work on registries , project supervision<br/>Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellows., project supervision<br/>Anthos : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellows., project supervision</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/>Editorial roles in a number of academic journals. Shares in private limited company (a legal separate entity in UK), but no salary/income/personal remuneration received.</p> |
| Mcevoy John William | <p><b>2023</b> Nothing to be declared</p> <p><b>2024</b> Nothing to be declared</p>  |
| Mihaylova Borislava | <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>Barts Charity, UK<br/>Bowel Research UK<br/>Cancer Research UK<br/>National Institute for Health and Care Research, UK</p>   |

## Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert              | Type of Relationship with Industry   |
|---------------------|--|
| Mihaylova Borislava | <b>2024</b><br><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>Barts Charity, UK<br>Bowel Research UK<br>Cancer Research UK<br>National Institute for Health and Care Research, UK   |
| Moelgaard Inge      | <b>2023</b><br>Nothing to be declared<br><hr/> <b>2024</b><br>Nothing to be declared   |
| Neubeck Lis         | <b>2023</b><br><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>Burdett Trust for Nursing<br>Chief Scientists Office<br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Sanofi Aventis : Risk Factors and Prevention<br><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br>Daiichi Sankyo : Atrial fibrillation screening, Principal Investigator<br><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br>Consultant Editor British Journal of Cardiac Nursing<br><hr/> <b>2024</b><br><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br>Burdett Trust for Nursing<br>Chief Scientists Office<br><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br>Consultant Editor British Journal of Cardiac Nursing |

## Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                    | Type of Relationship with Industry |   |
|---------------------------|------------------------------------|---|
| Prescott Eva              | <b>2023</b>                        | Nothing to be declared  |
|                           | <b>2024</b>                        | Nothing to be declared  |
| Rocca Bianca              | <b>2023</b>                        | <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>Cancer UK</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Aboca, SRL : Other</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/>Editorial Board of: Assistant Editor Diabetes and Vascular Disease Research Advisory Board: Pharmadvances. Associate Editor: Cardiovascular Drugs and Therapy, Clinical Pharmacology Editorial Board: Bleeding, Thrombosis, and Vascular Biology Associate Editor. Frontiers in Drug Safety and Regulation Section on Cardiovascular Drug Safety Associate Editor for European Cardiology Review Editorial Board European Journal of Preventive Cardiology Editorial Board Journal of Thrombosis and Thrombolysis Editorial Board International Journal of Cardiology</p> |
|                           | <b>2024</b>                        | <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/>Cancer UK</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br/>Bayer AG : Pharmacology and Pharmacotherapy</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br/>Bios Therapy : Substance Based medical devices in obesity, site investigator</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine.</b><br/>ISTH, Italian Society of Thrombosis and Haemostasis (SISST), Italian Society of Pharmacology (SIF), Mediterranean League against Thrombosis</p>  |
| Rossello Francisco Javier | <b>2023</b>                        | Nothing to be declared  |

## Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert                    | Type of Relationship with Industry |  |
|---------------------------|------------------------------------|--|
| Rossello Francisco Javier | <b>2024</b>                        | <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/> Associate editor of Heart - <a href="https://heart.bmj.com/pages/editorial-board">https://heart.bmj.com/pages/editorial-board</a> Associate Statistical Editor of Circulation: Cardiovascular Quality and Outcomes - <a href="https://www.ahajournals.org/circoutcomes/editorial-board">https://www.ahajournals.org/circoutcomes/editorial-board</a></p>   |
| Sannino Anna              | <b>2023</b>                        | Nothing to be declared   |
|                           | <b>2024</b>                        | Nothing to be declared   |
| Tanner Felix C            | <b>2023</b>                        | <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> Swiss Heart Foundation</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b><br/> Philips : Echocardiography</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/> Secretary, UEMS Cardiac Section Board, Swiss Institute for Medical Education Board, Swiss Heart Foundation Editorial Board, International Journal of Cardiology Editorial Board, Journal of Clinical Medicine Editorial Board, Swiss Medical Weekly Editorial Board, Cardiovascular Medicine</p> |
|                           | <b>2024</b>                        | <p><b>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity</b><br/> Swiss Heart Foundation</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b><br/> Secretary, UEMS Cardiac Section Board, Swiss Institute for Medical Education Board, Swiss Heart Foundation Editorial Board, International Journal of Cardiology Editorial Board, Journal of Clinical Medicine Editorial Board, Swiss Medical Weekly</p>  |

## Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert              | Type of Relationship with Industry  |
|---------------------|---|
| Wojakowski Wojciech | <b>2023</b><br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Boehringer Ingelheim : Chronic Heart Failure<br>Boehringer-Ingelheim : Chronic Heart Failure, Stroke<br>Abbott Vascular : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Valvular Heart Disease<br>Bristol Myers Squibb : Myocardial Disease<br>Pfizer : Stroke  |
|                     | <b>2024</b><br><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Boehringer Ingelheim : Chronic Heart Failure<br>Abbott Vascular : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Valvular Heart Disease<br>Medtronic : Hypertension<br>Bristol Myers Squibb : Myocardial Disease<br>CroiValve : Valvular Heart Disease   |
| Zeppenfeld Katja    | <b>2023</b><br><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b><br>Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)<br><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b><br>Biosense Webster : Investigator initiated research, ventricular arrhythmias, PI |
|                     | <b>2024</b><br>Nothing to be declared   |